TREM2 upregulation is considered a risk factor in AD because it can affect cholesterol, myelin, and phospholipid metabolism, negatively influencing the pathogenesis of the disease at both the CNS and periphery [101] and being more injurious at the early stages [102]. Here, TREM2 is linked to Alzheimer disease.